Search results
Results from the WOW.Com Content Network
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature ...
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo ...
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lowering drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Rank Year Purchaser Target Value (in billions USD) Value (adjusted for inflation) 1 2015 Pfizer: Allergan, plc: 160 206 In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation).
Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its ... Lilly recorded a total of $2 billion from its GLP-1 products in 2023, while Novo Nordisk pocketed ...
Amgen (NASDAQ: AMGN) is a top drugmaker whose shares have risen by more than 70% in five years, ... In 2023, it brought in $7.4 billion in free cash and its dividend payout amounted to $4.6 billion.
For premium support please call: 800-290-4726 more ways to reach us